Financial Results
FY/Q4 2025 – Coming soon!
Fresenius will publish its Q4 2025 results on February 25, 2026. The conference call will take place at 1:30 pm (CET). The dial-in details will follow soon.
As a service to investors and sell-side analysts, we provide an Aide Memoire ahead of its quiet period starting February 4, 2026. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. The Aide Memoire may prove helpful in assessing Fresenius’ financial performance ahead of the publication of its Q4/25 financial results on February 25, 2026.
Q3/25 Results
WebcastDocuments
Q4/25 Aide Memoire (PDF)Selected Key Figures Q3/2025
GROUP REVENUE 1
€ 5477 m
+ 6% 2
Q3/24: €5,303 m
GROUP EBIT 1
€ 574 m
+6% 3
Q3/24: €552 m
NET INCOME 1, 4
€ 351 m
+14% 3
Q3/24: €312 m
EPS 1, 4
€ 0.62
+14% 3
Q3/24: €0.55
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Growth rate at constant currency (cc) and adjusted for Argentina hyperinflation
4 Excluding Fresenius Medical Care
Revenue by business segment
| € in millions | Q3/25 | Q3/24 | Growth at actual rates | Growth at constant rates | Organic growth1 | Acquisitions/Divestitures | % of total revenue |
|---|---|---|---|---|---|---|---|
Fresenius Kabi | 2,141 | 2,114 | 1% | 6% | 7%1 | -1% | 39% |
Fresenius Helios | 3,240 | 3,082 | 5% | 5% | 5% | 0% | 59% |
Total | 5,477 | 5,303 | 3% | 5% | 6% | 0% | 100%2 |
-
1 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
2 Remaining 2% Corporate/Other revenue
Before special items